Can MTRR rs1801394 GG impair methyl-B12 recycling even when serum B12 and MMA are normal?

Intracellular vitamin B12 metabolism is highly compartmentalized, meaning that systemic markers of vitamin status often fail to reflect localized intracellular bottlenecks.

Mechanistic explanations

• MTRR enzymatic impairment: The MTRR rs1801394 GG (A66G) genotype encodes a variant of methionine synthase reductase with an approximately 4-fold reduction in activity. This deficit directly impairs the recycling of oxidized cobalamin back into active methylcobalamin (methyl-B12), leaving cytosolic methionine synthase inactive and elevating plasma homocysteine.
• Intracellular compartmentalization: Intracellular cobalamin metabolism is split between two distinct pathways. The mitochondrial pathway utilizes adenosylcobalamin as a cofactor for methylmalonyl-CoA mutase, whereas the cytosolic pathway requires methyl-B12 for the remethylation of homocysteine to methionine.

Diagnostic limitations

• Limits of serum B12 and MMA: Total serum B12 primarily measures cobalamin bound to haptocorrin, which is biologically inactive and does not reflect actual tissue delivery or cellular uptake. Meanwhile, optimal mitochondrial methylmalonic acid (MMA) levels only confirm adequate mitochondrial mutase activity.
• Masked cytosolic inefficiency: Because of this strict metabolic division, selective cytoplasmic recycling defects—such as those driven by the MTRR GG genotype—impair the methylation-arm pathway while leaving mitochondrial MMA levels entirely normal. Consequently, standard panels may overlook a functional cytosolic B12 deficiency.

Bottom line

• High serum vitamin B12 and optimal MMA levels do not rule out functional methylation-arm B12 inefficiency; the MTRR rs1801394 GG genotype impairs cytosolic methyl-B12 recycling independently of mitochondrial pathways, though supplementation with pre-activated methylcobalamin can directly bypass this metabolic bottleneck.